Created specifically for von Willebrand disease (VWD) bleeding episodes1
VONVENDI is the first and only recombinant von Willebrand factor (rVWF) treatment approved for on-demand and surgery for adults with all types of VWD (Type 1, Type 2, and Type 3).1,2 It helps reduce the number of bleeding episodes and is the only treatment approved for prophylaxis in adults with severe Type 3 VWD receiving on-demand therapy.1
Key facts about VONVENDI
Manufactured without human blood or plasma
VONVENDI is recombinant, meaning it's made without using human blood. This technology avoids the risk of spreading diseases through infected human blood.3
Can be used with or without recombinant FVIII as directed
Depending on your specific situation, your healthcare provider will decide if you may use VONVENDI by itself, or if you require additional recombinant FVIII (rFVIII).1
Approved for three different uses
Your healthcare provider may prescribe VONVENDI for three different uses: on-demand treatment of bleeds, to prevent excessive bleeding during and after surgery, and to reduce the number of bleeding episodes when used regularly (prophylaxis).1
VONVENDI can be used on a routine to reduce the number of bleeds (prophylaxis) in adults with severe Type 3 VWD receiving on-demand therapy1
VONVENDI is used in adults (age 18 years and older) diagnosed with von Willebrand disease to:
treat and control bleeding episodes
prevent excessive bleeding during and after surgery
reduce the number of bleeding episodes when used regularly (prophylaxis) in adults with severe Type 3 von Willebrand disease receiving on-demand therapy
Who should not use VONVENDI?
You should not use VONVENDI if you:
Are allergic to any ingredients in VONVENDI
Are allergic to mice or hamsters
VONVENDI Prescribing Information
Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment
Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
You're now leaving this site
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.